Evidence map›Paper›PMID 41667150›Full record

ArticleJournal for immunotherapy of cancer2026

CD4

Xi Rao, Kateryna Onyshchenko, Meidan Wang, Ren Luo, Xuanwei Zhang, Liqun Wang, Siegmar Kuhn, Yizhou Yang, Simone Gaedicke, Anca-Ligia Grosu and 2 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xi RaoDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Kateryna OnyshchenkoDepartment of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0002-9692-1861
Meidan WangDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Ren LuoDepartment of Thoracic Oncology Ward, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, Sichuan, China.
Xuanwei ZhangDepartment of Thoracic Oncology Ward, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, Sichuan, China.
Liqun WangDepartment of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Siegmar KuhnDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Yizhou YangDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-6411-1178
Simone GaedickeDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Anca-Ligia GrosuDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Elke FiratDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Gabriele NiedermannDepartment of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany gabriele.niedermann@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0001-9508-5497

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe local effect of radiotherapy (RT) is enhanced by CD8

methodsWe tested these regimens in B16 melanoma and C51 colon carcinoma models in mice with one irradiated and one non-irradiated tumor on opposite flanks.

resultsIn both models, RT/αPD-1/αCTLA-4 elicited a stronger abscopal response than RT/αPD-1/IL-2c. In the C51 model, RT/αPD-1/αCTLA-4 achieved a 61.5% abscopal cure rate, dependent on both CD8

conclusionsThese results demonstrate that an RT-based combination therapy that robustly induces CD4

Indexed as

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCross-PrimingMelanoma, ExperimentalAnimalsAntigens, NeoplasmFemaleMiceMice, Inbred C57BLAntigens, NeoplasmAbscopalImmunotherapyRadiotherapy/radioimmunotherapy

Identifiers

PMID41667150
PMCPMC12911821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.